Peramivir: Difference between revisions
m Taxobox tidy up or gen fixes using AWB |
Company and Peramivir emergency use request form |
||
| Line 71: | Line 71: | ||
Biocryst has donated 1200 courses of treatment to the US department of Health and Human Services.<ref>http://www.reuters.com/article/pressRelease/idUS10036+24-Oct-2009+PRN20091024</ref> |
Biocryst has donated 1200 courses of treatment to the US department of Health and Human Services.<ref>http://www.reuters.com/article/pressRelease/idUS10036+24-Oct-2009+PRN20091024</ref> |
||
==External Resources== |
|||
*[http://www.biocryst.com/peramivir BioCryst Pharmaceuticals, Inc.] |
|||
*[http://emergency.cdc.gov/h1n1antivirals/3.asp Peramivir CDC/FDA EUA request form] |
|||
==References== |
==References== |
||
Revision as of 20:13, 11 November 2009
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Pharmacokinetic data | |
| Bioavailability | 100% (IV) |
| Elimination half-life | 7.7 to 20.8 hour in patients with normal renal function |
| Excretion | renal |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C15H28N4O4 |
| Molar mass | 328.407 g/mol g·mol−1 |
Peramivir is an experimental antiviral drug being developed by BioCryst Pharmaceuticals for the treatment of influenza.
Peramivir is a neuraminidase inhibitor, acting as a transition-state analogue inhibitor of influenza neuraminidase and thereby preventing new viruses from emerging from infected cells.
The development of peramivir is supported by the US Department of Health and Human Services as part of the US government's effort to prepare against the threat of an influenza pandemic.[1]
The drug has had a long history. An oral formulation was abandoned by Johnson and Johnson due to poor bioavailability.[2] BioCryst Pharmaceuticals is now developing a injectable version, in partnership with Green Cross Pharmaceuticals in South Korea and with Shionogi Pharmaceuticals in Japan. The drug is in Phase II studies.[3][4]
Use in treating Influenza A (H1N1) "Swine Flu"
In October 2009, it was reported that the experimental antiviral drug Peramivir had been effective in treating serious cases of swine flu.[5] On October 23, the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization for Peramivir, allowing the use of the drug in intravenous form for hospitalized patients only in cases where the other available methods of treatment are ineffective or unavailable;[6] for instance, if Tamiflu resistance develops and a person is unable to take Relenza via the inhaled route. Peramivir is currently the only intravenous option for treating swine flu.
In Tamiflu resistant cases, peramivir is not recommended due to reduced sensitivity conferred by Tamiflu resistance.[7]
Biocryst has donated 1200 courses of treatment to the US department of Health and Human Services.[8]
External Resources
References
- ^
"HHS Pursues Advance Development of New Influenza Antiviral Drug" (Press release). US Department of Health and Human Services. 2007-01-04. Retrieved 2007-05-25.
{{cite press release}}: Check date values in:|date=(help) - ^
Pollack, Andrew (2005-10-07). "Talk of Bird Flu Pandemic Revives Interest in Passed-Over Drugs". New York Times. Retrieved 2007-05-25.
{{cite news}}: Check date values in:|date=(help) - ^
"Evaluation of the Efficacy and Safety of Peramivir in Subjects With Uncomplicated Acute Influenza". National Institutes of Health. 2007-03-16. Retrieved 2007-05-25.
{{cite web}}: Check date values in:|date=(help) - ^
"Evaluation of the Efficacy and Safety of Peramivir in Adults With Acute Serious or Potentially Life-Threatening Influenza". National Institutes of Health. 2007-03-28. Retrieved 2007-05-25.
{{cite web}}: Check date values in:|date=(help) - ^ "Life-Saving H1N1 Drug Unavailable to Most". CBS Evening News. Atlanta, GA, USA: CBS Interactive. 2009-10-19. Retrieved 2009-10-20.
- ^ http://www.reuters.com/article/pressRelease/idUS10540+24-Oct-2009+PRN20091024
- ^ http://www.palmbeachpost.com/health/content/local_news/epaper/2009/10/28/a1a_antiviral_1029.html
- ^ http://www.reuters.com/article/pressRelease/idUS10036+24-Oct-2009+PRN20091024